These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 3325930

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy.
    Rowen RC, Mullenix TA, Arroyo JC, Voris JC.
    Drug Intell Clin Pharm; 1988 Oct; 22(10):773-6. PubMed ID: 3147888
    [Abstract] [Full Text] [Related]

  • 43. [In vitro study of the combination of pefloxacin with other antibiotics against Pseudomonas aeruginosa and Streptococcus group D].
    Zuccarelli M, Attisso MA, Simeon de Buochberg M, Dusart G.
    Pathol Biol (Paris); 1987 May; 35(5):581-5. PubMed ID: 3112710
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [In-vivo bacteriostatic and bactericidal activity of pefloxacine].
    Meyran M, Thabaut A.
    Pathol Biol (Paris); 1986 May; 34(5):349-52. PubMed ID: 3095772
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Respiratory infections in patients undergoing mechanical ventilation.
    Rello J, Lisboa T, Koulenti D.
    Lancet Respir Med; 2014 Sep; 2(9):764-74. PubMed ID: 25151022
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. [New oral quinolone compounds in chronic bronchitis].
    Davies BI, Maesen FP, Teengs JP, Baur C.
    Infection; 1986 Sep; 14 Suppl 1():S73-8. PubMed ID: 2937739
    [Abstract] [Full Text] [Related]

  • 50. Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents.
    Eron LJ, Gentry LO.
    Diagn Microbiol Infect Dis; 1992 Jul; 15(5):435-9. PubMed ID: 1643820
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections.
    Tatsis G, Tsoukalas G, Hatzinikolaou V, Boulbasakos G, Jordanoglou J.
    J Int Med Res; 1996 Jul; 24(6):478-81. PubMed ID: 8959532
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Therapeutic contribution of the new quinolones].
    Wolff M.
    Rev Prat; 1987 Apr 11; 37(21):1209-14. PubMed ID: 3474759
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Cephalosporins, vancomycin, aminoglycosides and other drugs, especially in combination, for the treatment of methicillin-resistant staphylococcal infections.
    Klastersky J, Van der Auwera P.
    J Antimicrob Chemother; 1986 Mar 11; 17 Suppl A():19-24. PubMed ID: 2940212
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Clinical evaluation of cefamandole nafate.
    Rosett W, Hodges GR, Harms J, Gerjarusak P, Dworzack D, Hinthorn DR, Liu C.
    Am J Med Sci; 1977 Mar 11; 274(2):153-61. PubMed ID: 341707
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.